Risk factors of symptomatic patent ductus arteriosus in very-low-birth-weight preterm infants
Keywords:
patent ductus arteriosus, very-low-birth-weight preterm infants, respiratory distress syndrome, maternal medical conditionsAbstract
Background: Symptomatic patent ductus arteriosus (PDA) can lead to complications, mortality and long term disability. Understanding the risk factors associated with symptomatic PDA can guide treatment and prevention.
Objective: To study the factors contributing to the development of patent ductus arteriosus and its associated complications in very-low-birth-weight (VLBW) preterm infants.
Methods: A retrospective study was conducted on very-low-birth-weight preterm infants diagnosed with symptomatic PDA who requiring treatment, compared with those without symptoms, from 2018 to 2023. Multivariate logistic regression analysis was used to find factors influencing the manifestation of symptomatic patent ductus arteriosus.
Result: Factors influencing the manifestation of symptomatic PDA included PDA size (aOR 67.41, 95%CI 6.47, 701.92), surfactant therapy for respiratory distress syndrome (aOR 43.04, 95%CI 2.66, 697.26). Complications associated with symptomatic PDA included increase in ventilator utilization (OR 26.74, 95%CI 0.35, 69.07), inotropic agents usage (OR 13.23, 95%CI 2.98, 58.71), bronchopulmonary dysplasia (OR 7.40, 95%CI 3.36, 16.30), and acute kidney injury (OR 10.23, 95%CI 1.26, 82.71).
Conclusion: The incidence of symptomatic patent ductus arteriosus requiring treatment in VLBW preterm infants is relatively high in Lampang Hospital. Reducing the incidence rate of respiratory distress syndrome in VLBW preterm infants may prevent this condition.
Downloads
References
Hamrick SEG, Sallmon H, Rose AT, Porras D, Shelton EL, Reese J, et al. Patent ductus arteriosus of the preterm infant. Pediatrics. 2020;146(5):e20201209.
Supapannachart S, Limrungsikul A, Khowsathit P. Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: A randomized trial at Ramathibodi Hospital. J Med Assoc Thai. 2002;85:S1252-8.
วาสนา ปรางค์วัฒนากุล. ผลลัพธ์และอัตราการเกิดภาวะแทรกซ้อนของการผ่าตัดเส้นเลือดเกิน (PDA clipping) และการให้ยา Ibuprofen หรือ Indomethacin ในทารกแรกเกิดของโรงพยาบาลพระปกเกล้า จังหวัดจันทบุรี. 2563;37:16-25.
ธัญลักษมณ์ แง้เจริญกุล. ผลลัพธ์และอัตราการเกิดภาวะแทรกซ้อนของการให้ยา Ibuprofenในการรักษาทารกเกิดก่อนกำหนดที่มีภาวะ PDA ในโรงพยาบาลนครพนม. วารสารโรงพยาบาลนครพนม. 2566;10:1-12.
Semberova J, Sirc J, Miletin J, Kucera J, Berka I, Sebkova S, et al. Spontaneous closure of patent ductus arteriosus in infants ≤1500 g. Pediatrics. 2017;140:e20164258.
El-Khuffash A, Levy PT, Gorenflo M, Frantz ID. The definition of a hemodynamically significant ductus arteriosus. Pediatr Res. 2019;85:740–1.
Gillam-Krakauer M, Reese J. Diagnosis and management of patent ductus arteriosus. NeoReviews. 2018;19:e394–402.
Parkerson S, Philip R, Talati A, Sathanandam S. Management of patent ductus arteriosus in premature infants in 2020. Front Pediatr. 2020;8:590578.
El Hajjar M, Vaksmann G, Rakza T, Kongolo G, Storme L. Severity of the ductal shunt: A comparison of different markers. Arch Dis Child Fetal Neonatal Ed. 2005;90:F419-422.
อุเทน บุญมี, ปริมพัชร์ ไวทยวงศ์สกุล. สูตร T-formula สำหรับประเมินความรุนแรงของโรคหลอดเลือดเกินในเด็กแรกเกิด. Mahidol R2R e-Journal. 2562;6(1): http://doi.org/10.14456/jmu.2019.3
Kumar A, Lakkundi A, McNamara PJ, Sehgal A. Surfactant and patent ductus arteriosus. Indian J Pediatr. 2010;77:51–5.
Gillam-Krakauer M, Cotton RB, Reese J. Patent ductus arteriosus. In: Feld LG, Mahan JD, Lorenz JM, Seigel WM, eds. Succinct pediatrics: Evaluation and management for newborn, genetic, neurologic, and developmental-behavioral disorders. Elk Grove Village, IL: American Academy of Pediatrics; 2017. P. 137–50.
Vucovich MM, Cotton RB, Shelton EL, Goettel JA, Ehinger NJ, Poole SD, et al. Aminoglycoside-mediated relaxation of the ductus arteriosus in sepsis-associated PDA. American Journal of Physiology-Heart and Circulatory Physiology. 2014;307:H732–40.
Nealon E, Rivera BK, Cua CL, Ball MK, Stiver C, Boe BA, et al. Follow-up after percutaneous patent ductus arteriosus occlusion in lower weight infants. J Pediatr. 2019;212:144-150.e3.
Clyman RI, Hills NK, Cambonie G, Debillon T, Ligi I, Gascoin G, et al. Patent ductus arteriosus, tracheal ventilation, and the risk of bronchopulmonary dysplasia. Pediatr Res. 2022;91:652–8.
Majed B, Bateman DA, Uy N, Lin F. Patent ductus arteriosus is associated with acute kidney injury in the preterm infant. Pediatr Nephrol. 2019;34:1129–39.
Kikuchi N, Goto T, Katsumata N, Murakami Y, Shinohara T, Maebayashi Y, et al. Correlation between the closure time of patent ductus arteriosus in preterm infants and long-term neurodevelopmental outcome. JCDD. 2024;11:26.
Vuttipittayamongkol P. Risk factors of suspected development delay of low birth weight infants in Lampang Hospital. Paper presented at: Hornets; 2023 Jul 26; Prayao university.
Qian A, Jiang S, Gu X, Li S, Lei X, Shi W, et al. Treatment of patent ductus arteriosus and short-term outcomes among extremely preterm infants: a multicentre cohort study. eClinicalMedicine. 2024;67:102356.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 The Royal College of Pediatricians Of Thailand
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
